EMEA-001609-PIP01-14

Key facts

Active substance
  • Norovirus GI.1 virus-like particle antigen
  • norovirus GII.4 virus-like particle antigen
Therapeutic area
Vaccines
Decision number
P/0125/2015
PIP number
EMEA-001609-PIP01-14
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of acute norovirus gastroenteritis
Route(s) of administration
Intramuscular use
Contact for public enquiries
Takeda Vaccines, Inc.

Tel. +1 6174 442147
E-mail: amy.atwood@takeda.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating